We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

68 hedge funds and large institutions have $158M invested in Spyre Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

2% more capital invested

Capital invested by funds: $154M → $158M (+$3.44M)

0.07% more ownership

Funds ownership: 2.78% → 2.85% (+0.07%)

4% less funds holding

Funds holding: 71 → 68 (-3)

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

Holders
68
Holders Change
-3
Holders Change %
-4.23%
% of All Funds
1.34%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.08%
New
9
Increased
20
Reduced
16
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAWC
P.A.W. Capital
Connecticut
+$785K
2
Deutsche Bank
Deutsche Bank
Germany
+$445K
3
SCA
Snowden Capital Advisors
New York
+$403K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$400K
5
Two Sigma Investments
Two Sigma Investments
New York
+$390K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$3.85M
2
N
Nuveen
North Carolina
-$385K
3
DAM
Deltec Asset Management
New York
-$192K
4
AG
Algert Global
California
-$180K
5
Squarepoint
Squarepoint
New York
-$178K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$21.9M – – –
NCM
2
Nantahala Capital Management
Connecticut
$21.8M – – –
BlackRock
3
BlackRock
New York
$14.7M +$155K +788 +1%
BBA
4
Baker Bros. Advisors
New York
$13.1M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$11.2M – – –
ACM
6
Aisling Capital Management
New York
$9.86M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.02M +$400K +2,037 +5%
Marshall Wace
8
Marshall Wace
United Kingdom
$6.37M +$258K +1,312 +4%
RSCM
9
Rock Springs Capital Management
Maryland
$6.11M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$4.4M +$119K +608 +3%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$4.05M -$41.6K -212 -1%
State Street
12
State Street
Massachusetts
$3.55M +$260K +1,324 +8%
SCM
13
Soleus Capital Management
Connecticut
$3.5M +$3.6M +18,327 New
Goldman Sachs
14
Goldman Sachs
New York
$3.38M +$55.4K +282 +2%
UOTTAIMCU
15
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$2.46M +$2.53M +12,906 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.39M +$5.5K +28 +0.2%
AG
17
Artal Group
Luxembourg
$2.29M – – –
Northern Trust
18
Northern Trust
Illinois
$2.24M -$66.7K -340 -3%
RWM
19
Ritholtz Wealth Management
New York
$1.87M -$157K -800 -8%
A
20
Abingworth
United Kingdom
$1.83M – – –
Russell Investments Group
21
Russell Investments Group
United Kingdom
$1.16M – – –
BCM
22
Bridgeway Capital Management
Texas
$783K – – –
PAWC
23
P.A.W. Capital
Connecticut
$764K +$785K +4,000 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$691K +$5.89K +30 +0.8%
N
25
Nuveen
North Carolina
$680K -$385K -1,963 -36%
1
2 3 4

SYRE Hedge Fund Activity: Q4 2019 in Review

68 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2019, worth a combined $158M — up 2.2% from $154M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of SYRE and 9 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 20 added.

The largest buyer was P.A.W. Capital, opening a new position worth an estimated $785K. The largest seller was Deerfield Management, exiting entirely with an estimated $3.85M sold.

  • 68 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2019, down from 71 in Q3 2019.
  • Funds reported $158M of Spyre Therapeutics stock for Q4 2019, up 2.2% quarter-over-quarter.
  • 9 funds opened new Spyre Therapeutics positions in Q4 2019 and 12 closed out, a net change of -3 holders.
  • The largest Spyre Therapeutics buyer in Q4 2019 was P.A.W. Capital, an estimated $785K added.
  • The largest Spyre Therapeutics seller in Q4 2019 was Deerfield Management, an estimated $3.85M sold.

Based on aggregated 13F filings for Q4 2019.